Bridge Biotherapeutics Inc
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for … Read more
Bridge Biotherapeutics Inc (288330) - Total Liabilities
Latest total liabilities as of September 2025: ₩7.15 Billion KRW
Based on the latest financial reports, Bridge Biotherapeutics Inc (288330) has total liabilities worth ₩7.15 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bridge Biotherapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Bridge Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bridge Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Bridge Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yeh-Chiang Technology
TWO:6124
|
Taiwan | NT$1.40 Billion |
|
Oceana Lithium Ltd
AU:OCN
|
Australia | AU$415.17K |
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩15.22 Billion |
|
Mitrabahtera Segara Sejati Tbk
JK:MBSS
|
Indonesia | Rp23.93 Million |
|
N. B. I. Industrial Finance Company Limited
NSE:NBIFIN
|
India | ₹1.89 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Bridge Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bridge Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bridge Biotherapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Bridge Biotherapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩7.25 Billion | -51.18% |
| 2023-12-31 | ₩14.84 Billion | +54.79% |
| 2022-12-31 | ₩9.59 Billion | +165.66% |
| 2021-12-31 | ₩3.61 Billion | -15.70% |
| 2020-12-31 | ₩4.28 Billion | -9.26% |
| 2019-12-31 | ₩4.72 Billion | -91.81% |
| 2018-12-31 | ₩57.59 Billion | +93.12% |
| 2017-12-31 | ₩29.82 Billion | +109.12% |
| 2016-12-31 | ₩14.26 Billion | -- |